Skip to main content

Advertisement

Table 4 Cox proportional hazards regression of all patients for intracranial progression

From: Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

Variables Hazard ratio (95% CI) p value
Age > 65 1.12 (0.771 to 1.615) 0.561
Sex (male) 0.93 (0.617 to 1.395) 0.718
Smoking 1.06 (0.594 to 1.900) 0.838
EGFR mutation
 L858R only Reference  
 Del 19 only 0.94 (0.643 to 1.363) 0.729
 Uncommon mutation 2.26 (0.802 to 6.341) 0.123
 Complex mutations 2.95 (1.050 to 8.264) 0.040
Initial brain metastases number ≥ 3 1.16 (0.800 to 1.685) 0.432
RT to brain before 1st PD 0.80 (0.535 to 1.191) 0.270
Brain tumor excision 0.91 (0.608 to 1.362) 0.209
TKI
 Gefitinib Reference  
 Erlotinib 0.85 (0.568 to 1.283) 0.447
 Afatinib 1.00 (0.602 to 1.662) 1.000